- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
304 CHAPTER 6 Urological neoplasia
Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
Following radical orchiectomy and formal staging, the patient may require a retroperitoneal lymph node dissection (RPLND). Joint management involves urology and medical oncology in most cases of NSCGT.
In the presence of elevated AFP, a seminoma would be managed as for teratoma. Combination chemotherapy, introduced in the 1980s, revolutionized the treatment of metastatic testicular teratoma, which was hitherto virtually untreatable.
The IGCCCG prognostic staging is often used in treatment planning at some centers. General treatment options following radical orchiectomy and staging for NSCGT are outlined here (see Table 6.18 for stage grouping).
Stage I
•Surveillance is appropriate for reliable patients with no risk factors. It has a 25–30% relapse rate.
•Requires close follow-up with imaging (CT, CXR), tumor markers, and physical examination
•RPLND: modified unilateral template/nerve-sparing. Up to 70–75% will be pathologically negative (pN0).
•RPLND offers cure in 95% with negative nodes and may cure lowvolume nodal disease. Only 5% will relapse.
•Chemotherapy with two cycles of bleomycin, etoposide, cisplatin (BEP) yields 95% survival.
Stage IIa/IIb
Controversy exists regarding the most effective treatment regimen. Options include RPNLD with modified bilateral template, RPNLD + adjuvant chemotherapy, or primary chemotherapy.
•RPNLD and no tumor found: observe
•RPNLD and positive nodes: two cycles of adjuvant chemotherapy
•RPNLD and high-volume disease or residual tumor left behind: three cycles adjuvant chemotherapy
Stage IIC or III
•Chemotherapy is the initial treatment, with either 3 or 4 cycles depending on risk. Complete responses are frequently observed.
•Partial responses with residual retroperitoneal masses undergo full bilateral RPNLD (nerve-sparing, if applicable). Follow-up is based on pathological findings:
•Residual masses: fibrosis in 40%, teratoma in 40%, and viable malignancy in 20%
•Malignancy present and post-resection tumor markers elevated or tumor left behind: use salvage chemotherapy
•Malignancy present and post-resection tumor markers normal and no tumor left behind: 2 cycles of chemotherapy can be given
•Teratoma/fibrosis only: observation only
TESTICULAR CANCER: NSGCT 305
Table 6.18 Simplified stage grouping for testis cancer, including S stage
Simplified stage groupings in testis cancer
Stage 0 |
|
Tis |
N0 |
M0 |
S0 |
|
||
Stage IA |
|
T1 |
N0 |
M0 |
S0 |
|
||
Stage IB |
|
T2–4 |
N0 |
M0 |
S0 |
|
||
Stage IS |
|
T any |
N0 |
M0 |
S 1–3 |
|
||
Stage IIA |
T any |
N1 |
M0 |
S 0/1 |
|
|||
Stage IIB |
|
T any |
N2 |
M0 |
S 0/1 |
|
||
Stage IIC |
T any |
N3 |
M0 |
S 0/1 |
|
|||
Stage IIIA |
T any |
N any |
M 1a |
S 0/1 |
|
|||
Stage IIIB |
T any |
N any |
M 0/1a |
S2 |
|
|||
Stage IIIC |
T any |
N any |
M 0/1a |
S3 |
|
|||
|
|
T any |
N any |
M1b |
S any |
|
||
|
|
|
|
|||||
a, nonregional nodes or pulmonary metastasis; b, other distant metastasis. |
|
|||||||
|
|
|
|
|
|
|
|
|
|
LDH |
|
hCG mIU/mL |
|
AFP ng/mL |
|
||
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
S0 |
Normal |
|
Normal |
|
Normal |
|
||
S1 |
<1.5 ULN |
<5000 |
|
<1000 |
|
|
|
|
S2 |
1.6–10 ULN |
5100–50,000 |
|
1100–10,000 |
|
|||
S3 |
>10.1 ULN |
>50,100 |
|
>10,100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
ULN, upper limit of normal.
•With no response to primary chemotherapy, consider salvage chemotherapy (ifosfamide, vinblastine, cisplatin), or salvage bone marrow transplant.
Chemotherapy
Regardless of histology, patients with advanced germ cell tumors (cIIB– cIII) and those with elevated tumor markers following radical orchiectomy (cIS) are treated initially with platinum-based chemotherapy based on IGCCCG risk stratification.
Good risk
Use BEP regimen every 21 days x3 cycles
•Bleomycin 30 U IV weekly
•Etoposide 100 mg/m2 IV x 5 days
•Cisplatin 20 mg/m2 IV x5 days
Or EP regimen every 21 day x4 cycles
•Etoposide 100 mg/m2 IV x5 days
•Cisplatin 20 mg/m2 IV x5 days
306 CHAPTER 6 Urological neoplasia
Intermediateor high-risk disease
Use 4 cycles BEP every 21 days (as above), or the following given every 21 days x 4 cycles:
•Etoposide 75 mg/m2 IV x 5 days
•Ifosfamide 1.2 g/m2 IV x 5 days
•Cisplatin 20 mg/m2 IV x 5 days
Chemotherapy complications
•Bleomycin: pulmonary toxicity causing pulmonary fibrosis that can be life threatening
•Cisplatin: nephrotoxicity, ototoxicity, peripheral neuropathy
•Etoposide (VP16): hematological toxicity, alopecia, vascular toxicity, metabolic syndrome
•Ifosfamide: hemorrhagic cystitis (can be reduced by the use of MESNA)
•Secondary malignancy: leukemias, lymphomas, skin malignancies
•Infertility: 50% will have normal sperm counts 2 years after chemotherapy, 25% will remain azoospermic (many patients with testicular cancer will have abnormal semen parameters before radical orchiectomy)
Surveillance and follow-up after treatment
Surveillance for low-risk disease requires the following. Patients who undergo definitive therapy can have less aggressive follow-up the first 2 years, but follow-up is also to 10 years. The risk of relapse is highest in the first 2 years.
•Year 1: monthly clinic visit with serum markers and chest X-ray, abdominal CT months 3, 6, 9, and 12
•Year 2: bi-monthly clinic visit with serum markers and chest X-ray, abdominal CT month 24
•Years 3, 4, and 5: 3-monthly clinic visit with serum markers and chest X-ray
•Annual clinic visit with serum markers and chest X-ray thereafter to 10 years
RPLND
RPLND is the gold-standard staging investigation following radical orchiectomy. In the United States, it is the preferred approach for patients at high risk for retroperitoneal relapse (predominant embryonal carcinoma, lymphovascular invasion, or extension into the tunica or scrotum) if serum tumor markers have normalized. In the UK, RPLND is used only to remove or debulk residual mass post-chemotherapy.
Retroperitoneal lymphadenopathy is usually the first and only evidence of extragonadal metastasis of teratoma. For low-stage disease, a modified nerve-sparing template is used.
Open RPLND is the standard, with laparoscopic techniques applied at some centers. It is a technically challenging procedure that requires significant expertise.
TESTICULAR CANCER: NSGCT 307
Left-sided testicular tumor
The limits of dissection include the left common iliac artery medially and inferiorly up to the aortic bifurcation. Dissection continues along the aorta to the inferior mesenteric artery (IMA), and above the IMA, the dissection is carried out to the lateral edge of the inferior vena cava. The superior limit of the dissection is the renal vessels bilaterally. The ureter and gonadal vessels are the limit laterally.
The spermatic cord stump (marked by a nonabsorbable suture at the time of radical orchiectomy) is included in the specimen.
Right-sided testicular tumor
The limits of dissection include the right common iliac artery medially and inferiorly up to bifurcation of the aorta. Dissection continues along the aorta up to the IMA. Superior to the IMA, the dissection is carried out to the left ureter. Superior limit is the renal hilum bilaterally. On the right side, lateral limit is the ureter and the gonadal vessels.
The stump of the spermatic cord is included in the specimen.
Post-chemotherapy RPLND
Post-chemotherapy RPLND and resection of residual masses involves a complete bilateral resection including the supra hilar nodes. In the setting of post-chemotherapy RPLND, 40% will have teratoma, and 10–15% will have viable germ cell tumor.
RPLND complications
There is <1% mortality. Perioperative morbidity is 5–25% (atelectasis, ileus, lymphocele, pancreatitis, chylous ascites). Late bowel obstruction also occurs (1–2%). Ejaculatory dysfunction, when present, can be markedly decreased with nerve-sparing templates.